ReviewMolecular biology reports2026
Unravelling the phytochemical complexity of neuroprotective plants: a metabolomics approach to Alzheimer's disease.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metabolomics is a comprehensive study of organisms at the metabolite level. The emergence of metabolomics as one of the 'omics' in systems biology perspectives has gained significance in relation to disease research. The use of metabolomics pipeline to unravel the potential of bioactive compounds in medicinal plants for benefiting mankind has become a powerful strategy for drug discovery. While traditional metabolite profiling has mainly classified medicinal plants according to broad biological activities, such as anti-inflammatory, anticancer, anti-diabetic and atherosclerosis effects, the non-targeted and targeted metabolomics offer a comprehensive approach for characterizing novel or previously unknown secondary metabolites providing a far more detailed approach. These advanced methodologies allow researchers to expand current research by providing deeper insight into how these compounds work and their underlying mechanisms at the molecular level. To investigate these metabolic shifts particularly in neurodegenerative diseases model, studies frequently use advanced analytical platform, such as nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS) to analyze metabolites in biofluids like blood, urine, and cerebrospinal fluid (CSF). This review will highlight recent metabolomics discoveries on unravelling the complex phytochemical composition of selected medicinal plants in producing neuroprotective bioactive compounds and therapeutic potential to combat neurodegenerative related disease especially Alzheimer's disease (AD).
Indexed as
Identifiers
42599532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.